Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.

Alfredo Addeo,Markus Joerger,Sacha I. Rothschild,E.I. Eboulet,Gilles Godar,Christine Waibel Pachinger,Simon Haefliger,Michael Mark,Eugenio Fernandez,Nicolas Mach,Laetitia A. Mauti,Martin Frueh

Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.

2021

Alfredo Addeo
Markus Joerger
Sacha I. Rothschild
E.I. Eboulet
Gilles Godar
Christine Waibel Pachinger
Simon Haefliger
Michael Mark
Eugenio Fernandez
Nicolas Mach
Laetitia A. Mauti
Martin Frueh

e21119Background: A substantial proportion of patients with squamous lung cell carcinoma (SQCLC) (46%) exhibit tumor overexpression of fibroblast growth factor receptor (FGFR) messenger ribonucleic...

Keywords:

Cancer research
in patient
Messenger RNA
Lung cancer
Medicine
non small cell
Cell
Lung
Phases of clinical research
Fibroblast growth factor receptor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations